Insulet Announces Agreements With Abbott and DexCom
On Wednesday, insulin pump maker Insulet (NASDAQ: PODD) announced agreements with Abbott (NYSE: ABT) and DexCom (NASDAQ: DXCM), two leading sellers of continuous glucose monitors (CGMs), to sell automated insulin delivery systems. Shares of Insulet were up by more than 2% on the news as of 2 p.m. EST.
The integrated systems will allow patients to have their insulin delivery controlled automatically according to their blood glucose levels using disposable CGMs and Insulet's wearable, tubeless insulin delivery pods. The systems will use Insulet's Omnipod Horizon system, which it expects to launch in the second half of 2020.
Image source: Getty Images.
Source Fool.com
